HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. A prospective study on efficacy and safety in a Saudi population.

AbstractAIM:
The goal of the present study was to prospectively assess the long-term clinical outcome of biologic modifying drug therapy in a population of Saudi rheumatoid arthritis (RA) patients.
PATIENTS AND METHODS:
This is the first prospective, long-term report on the efficacy and safety of biologic therapy in Saudi RA patients. It is a single center, observational study with a follow-up period of 3 years. Enrolled were 120 biologic naïve patients (94 women, 78.3 %; mean age 48.4 ± 17.9 years, mean disease duration 7.3 ± 3.9 years) with the diagnosis of RA (ACR/EULAR, 2010 criteria) who were inadequate responders to methotrexate and synthetic DMARDs.
RESULTS:
After 3 years, the mean Disease Activity Index-28 (DAS-28), Health Assessment Questionnaire (HAQ), Pain Score, ESR, and CRP values improved significantly. Of the 99 patients completing the 3-year follow-up, 35.3 % of patients achieved DAS-28 remission and 53.5 % achieved low disease activity, and 11.1 % of patients had moderate to high activity scores. At the 3-year follow-up, 80 % of patients had no evidence of significant radiographic progression (achieved < 0.5 of the mean total Sharp score). Infections were reported in 11.7 % and significantly correlated with conjugate use of oral prednisolone at doses above 5 mg/day, with chest infections being the most common type of infection (6.7 %).
CONCLUSION:
The results of this study can be understood as real-life clinical experience displaying the incremental benefit of biologic therapy in refractory disease when it is added to other optimal strategies. The study showed satisfying clinical and functional benefit with considerable safety.
AuthorsR H A Mohammed, H H Kewan, M Bukhari
JournalZeitschrift fur Rheumatologie (Z Rheumatol) Vol. 73 Issue 8 Pg. 746-53 (Oct 2014) ISSN: 1435-1250 [Electronic] Germany
PMID24682293 (Publication Type: Clinical Trial, Journal Article, Observational Study)
Chemical References
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Biological Products
  • Methotrexate
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (administration & dosage)
  • Antirheumatic Agents (administration & dosage)
  • Arthritis, Rheumatoid (diagnosis, drug therapy)
  • Biological Products (administration & dosage)
  • Chronic Disease
  • Drug Resistance
  • Female
  • Humans
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Molecular Targeted Therapy (methods)
  • Prospective Studies
  • Saudi Arabia
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: